Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

No cookies to display.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

No cookies to display.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

No cookies to display.

ADVERTISEMENT

Epinephrine (or Adrenaline) Nasal Spray for Treatment of Anaphylaxis 

Neffy (epinephrine nasal spray) has been approved by the FDA for the emergency treatment of Type I allergic reactions including life-threatening anaphylaxis. This provides an alternative route of administration of epinephrine to those (especially children) averse to injections and are faced with a life-threatening situation of anaphylaxis.  

Epinephrine is the only life-saving treatment for anaphylaxis. It is available so far only as an injection usually administered through intramuscular (IM) or intravenous (IV) route. Neffy is the first epinephrine product for the treatment of anaphylaxis that is not administered by injection.  

The approval of nasal spray is based on results from studies. The two routes viz. nasal spray and injection have shown comparable epinephrine blood concentrations following administration. They also showed similar increases in blood pressure and heart rate which are two critical effects of epinephrine in the treatment of anaphylaxis. 

Neffy is a single dose nasal spray administered into one nostril. A second dose (using a new nasal spray to the same nostril) may be given if there is no improvement in symptoms or symptoms worsen. Patients may need to seek emergency medical assistance for close monitoring.  

Contraindications are certain nasal conditions, like nasal polyps or a history of nasal surgery which may affect absorption, certain coexisting conditions and allergic reactions associated with sulfite. Patients with these conditions should consult with a health care professional to consider use of an injectable epinephrine product. Common side effects include throat irritation, tingling nose (intranasal paresthesia), headache, nasal discomfort, feeling jittery, tingling sensation (paresthesia), fatigue, tremor, runny nose (rhinorrhea), itchiness inside the nose (nasal pruritus), sneezing, abdominal pain, gum (gingival) pain, numbness in the mouth (hypoesthesia oral), nasal congestion, dizziness, nausea and vomiting.  

Allergic reactions are abnormal reactions of a person’s immune system to a substance that normally does not cause symp 

Anaphylaxis is considered a medical emergency. It is a severe, life-threatening allergic reaction that typically involves multiple parts of the body. Certain foods, medications and insect stings are common allergens that can induce anaphylaxis. Symptoms usually occur within minutes of exposure and include, but are not limited to, hives, swelling, itching, vomiting, difficulty breathing and loss of consciousness.  

The FDA granted the approval of Neffy to ARS Pharmaceuticals. 

*** 

References:  

  1. FDA Approves First Nasal Spray for Treatment of Anaphylaxis. Posted on 09 August 2024. Available at https://www.fda.gov/news-events/press-announcements/fda-approves-first-nasal-spray-treatment-anaphylaxis 

*** 

SCIEU Team
SCIEU Teamhttps://www.ScientificEuropean.co.uk
Scientific European® | SCIEU.com | Significant advances in science. Impact on humankind. Inspiring minds.

Subscribe to our newsletter

To be updated with all the latest news, offers and special announcements.

Most Popular Articles

Diagnosing Vitamin D Deficiency by Testing Hair Sample Instead of Blood Test

Study shows first step towards developing a test for...

The Fast Radio Burst, FRB 20220610A originated from a novel source  

Fast Radio Burst FRB 20220610A, the most powerful radio...

Is ‘Nuclear Battery’ coming of age?

Betavolt Technology, a Beijing based company has announced miniaturization...
- Advertisement -
93,396FansLike
47,369FollowersFollow
1,772FollowersFollow
30SubscribersSubscribe